Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -60.00% | 87.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -60.00% | 87.50% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -60.00% | 87.50% | |||
| SG&A Expenses | -0.66% | 9.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 16.34% | -18.91% | |||
| Total Operating Expenses | 64.98% | -13.94% | |||
| Operating Income | -65.03% | 13.96% | |||
| Income Before Tax | -262.26% | 8.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -262.26% | 8.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -262.26% | 8.99% | |||
| EBIT | -65.03% | 13.96% | |||
| EBITDA | -70.33% | 13.63% | |||
| EPS Basic | -222.56% | 26.30% | |||
| Normalized Basic EPS | -74.82% | 19.01% | |||
| EPS Diluted | -222.56% | 26.30% | |||
| Normalized Diluted EPS | -74.82% | 19.01% | |||
| Average Basic Shares Outstanding | 12.31% | 23.49% | |||
| Average Diluted Shares Outstanding | 12.31% | 23.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||